{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-026338","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.169277+00:00","generated_at":"2026-06-05T18:08:36.700128+00:00","sec_items":["1.01","2.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel acquires U.S. rights to Blueprint's pralsetinib for $15M plus milestones","bullets":["Purchase price $15M: $10M at first commercial sale, $5M one year after closing.","Up to $97.5M in commercial milestones and $5M in regulatory milestones.","Blueprint receives tiered royalties of 10-30% on net sales of pralsetinib products.","Pralsetinib is an approved RET inhibitor for metastatic NSCLC and advanced thyroid cancer.","Rigel expects to recognize product sales starting in Q3 2024 using its commercial infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-026338","json":"https://secwatch.observer/filing/0001104659-24-026338.json","markdown":"https://secwatch.observer/filing/0001104659-24-026338.md","text":"https://secwatch.observer/filing/0001104659-24-026338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924026338/0001104659-24-026338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924026338/tm246898d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:08:36.700128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}